Nkarta Inc.

2.34
-0.05 (-2.09%)
At close: Feb 06, 2025, 1:57 PM
undefined%
Bid 2.34
Market Cap 165.13M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.83
PE Ratio (ttm) -1.28
Forward PE n/a
Analyst Buy
Ask 2.35
Volume 239,676
Avg. Volume (20D) 1,609,256
Open 2.39
Previous Close 2.39
Day's Range 2.33 - 2.42
52-Week Range 2.08 - 16.24
Beta undefined

About NKTX

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 10, 2020
Employees 159
Stock Exchange NASDAQ
Ticker Symbol NKTX

Analyst Forecast

According to 5 analyst ratings, the average rating for NKTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 583.76% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
5 months ago
+3.22%
Nkarta shares are trading higher after the company... Unlock content with Pro Subscription
6 months ago
+13.96%
Nkarta shares are trading higher after the company appointed Nadir Mahmood as President.